GlassScriptPhysician profile
Melissa D Selke
NPI 1669488367
$1,704.91
in general payments reported to CMS, 2019-2025
23 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $143 · 2021: $96.73 · 2022: $245 · 2023: $161 · 2024: $246 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $428.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $219.39 | 2019-2024 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $209.77 | 2019-2024 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $209.15 | 2019-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $130.31 | 2019-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Pfizer INC. | $87.15 | 2019-2025 | |
| Amgen INC. | $46.42 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $42.01 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.41 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.00 | 2022 | |
| Glaxosmithkline, LLC. | $34.01 | 2019-2023 | Shingrix |
| Kowa Pharmaceuticals America, INC. | $28.78 | 2019-2022 | |
| Allergan, INC. | $24.36 | 2019 | |
| Astellas Pharma US INC | $22.64 | 2024 | Veozah |
| Exact Sciences Corporation | $22.20 | 2025 | The Cologuard Plus Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $18.14 | 2019 | |
| Bausch Health US, LLC | $15.01 | 2019 | |
| Sanofi Pasteur INC. | $15.00 | 2021 | |
| Amarin Pharma, INC. | $14.93 | 2020 | |
| Assertio Therapeutics, INC. | $14.91 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.68 | 2022 | |
| Biogen, INC. | $14.41 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Selke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.